Lambert-Eaton myasthenic syndrome (LEMS) is a paraneoplastic syndrome in which the immune system attacks the connection ...

Firdapse, a treatment for Lambert-Eaton myasthenic syndrome, has provided the majority of Catalyst's revenue in recent quarters. Write to Josh Beckerman at [email protected] About Dow Jones ...

In addition, patients with myasthenia gravis, the Lambert-Eaton myasthenic syndrome, Guillain-Barre syndrome, chronic demyelinating polyneuropathy, sarcoidosis, neuro-Behcet's disease, paraneoplastic ...

Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with Lambert-Eaton myasthenic syndrome ("LEMS"). "We are pleased that our sub-licensee, DyDo, has launched ...

Detailed price information for Catalyst Pharm Inc (CPRX-Q) from The Globe and Mail including charting and trades.